secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001493152-23-015941
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma Q1 net loss $3.9M; cash $51.5M; first patient dosed in Phase 2 Harmonic trial
--------------------------------------------------------------------------------

- Cash, cash equivalents, and marketable securities $51.5M as of March 31, 2023; cash runway into 2025.
- Net loss $3.9M ($0.36/share) for Q1 2023 vs $4.1M ($0.38/share) for Q1 2022.
- Dosed first patient in Phase 2 Harmonic trial for never-smoker NSCLC; multiple additional sites expected by mid-2023.
- IND submission for LP-184 anticipated this week; Phase 1A basket trial targeted for mid-2023 in solid tumors and CNS cancers.
- Formed subsidiary Starlight Therapeutics to develop LP-184 (STAR-001) for CNS and brain cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000149315223015941/0001493152-23-015941-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000149315223015941/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-015941

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer